[HTML][HTML] Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies
M Del Rio, C Mollevi, F Bibeau, N Vie, JF Emile… - European Journal of …, 2017 - Elsevier
Background Currently, metastatic colorectal cancer is treated as a homogeneous disease
and only RAS mutational status has been approved as a negative predictive factor in …
and only RAS mutational status has been approved as a negative predictive factor in …
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies
M Del Rio, C Mollevi, F Bibeau… - … journal of cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Currently, metastatic colorectal cancer is treated as a homogeneous disease
and only RAS mutational status has been approved as a negative predictive factor in …
and only RAS mutational status has been approved as a negative predictive factor in …
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
M Del Rio, C Mollevi, F Bibeau, N Vie… - European Journal of …, 2017 - europepmc.org
Background Currently, metastatic colorectal cancer is treated as a homogeneous disease
and only RAS mutational status has been approved as a negative predictive factor in …
and only RAS mutational status has been approved as a negative predictive factor in …
[引用][C] Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies
M Del Rio, C Mollevi, F Bibeau, N Vie, J Selves… - European Journal of …, 2017 - cir.nii.ac.jp
Molecular subtypes of metastatic colorectal cancer are associated with patient response to
irinotecan-based therapies | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
irinotecan-based therapies | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies
M del Rio, C Mollevi, F Bibeau, N Vie… - European Journal of …, 2017 - hal.science
BACKGROUND: Currently, metastatic colorectal cancer is treated as a homogeneous
disease and only RAS mutational status has been approved as a negative predictive factor …
disease and only RAS mutational status has been approved as a negative predictive factor …
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies
M Del Rio, C Mollevi, F Bibeau, N Vie, J Selves… - European Journal of …, 2017 - infona.pl
Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS
mutational status has been approved as a negative predictive factor in patients treated with …
mutational status has been approved as a negative predictive factor in patients treated with …
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies
M Del Rio, C Mollevi, F Bibeau, N Vie… - European Journal of …, 2017 - ejcancer.com
Background Currently, metastatic colorectal cancer is treated as a homogeneous disease
and only RAS mutational status has been approved as a negative predictive factor in …
and only RAS mutational status has been approved as a negative predictive factor in …